REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 209 filers reported holding REATA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.53 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $15,130,864 | -73.6% | 148,400 | -76.4% | 0.27% | -75.8% |
| Q1 2023 | $57,288,692 | +471.1% | 630,100 | +57.9% | 1.11% | +702.2% |
| Q3 2022 | $10,031,000 | -28.6% | 399,110 | -7.0% | 0.14% | -18.3% |
| Q1 2022 | $14,054,000 | +109.3% | 429,000 | +68.4% | 0.17% | +122.4% |
| Q4 2021 | $6,715,000 | -20.0% | 254,700 | +205.4% | 0.08% | -20.8% |
| Q3 2021 | $8,391,000 | +1764.7% | 83,400 | +1753.3% | 0.10% | +860.0% |
| Q1 2021 | $450,000 | -72.5% | 4,500 | -73.2% | 0.01% | -73.7% |
| Q3 2020 | $1,637,000 | -85.8% | 16,800 | -77.3% | 0.04% | -90.1% |
| Q2 2020 | $11,561,000 | -14.2% | 74,100 | -20.6% | 0.38% | -49.5% |
| Q1 2020 | $13,468,000 | -40.4% | 93,300 | -15.7% | 0.76% | +0.4% |
| Q4 2019 | $22,613,000 | +288.5% | 110,616 | +52.6% | 0.76% | +150.5% |
| Q3 2019 | $5,820,000 | +517.2% | 72,500 | +625.0% | 0.30% | +544.7% |
| Q2 2019 | $943,000 | – | 10,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |